702699-84-1

Basic information

• Product Name: 1,2-Ethanediamine,N2,N2-dimethyl-1-phenyl-,(1S)-(9CI)
• Synonyms: 1,2-Ethanediamine,N2,N2-dimethyl-1-phenyl-,(1S)-(9CI);N-((2S)-2-amino-2-phenylethyl)-N,N-dimethylamine;1,2-EthanediaMine,N2,N2-diMethyl-1-phenyl-(1S)-;(S)-N1,N1-DiMethyl-2-phenylethane-1,2-diaMine;(S)-N2,N2-Dimethyl-1-phenyl-1,2-ethanediamine 2HCl
• CAS NO: 702699-84-1
• Molecular Formula: C₁₀H₁₆N₂
• Molecular Weight: 164.25
• Product Categories: AMINETERTIARY
• Mol File: 702699-84-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 238.2 °C at 760 mmHg
• Flash Point: 91.2 °C
• Appearance: /
• Density: 0.983
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 1,2-Ethanediamine,N2,N2-dimethyl-1-phenyl-,(1S)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Ethanediamine,N2,N2-dimethyl-1-phenyl-,(1S)-(9CI)(702699-84-1)
• EPA Substance Registry System: 1,2-Ethanediamine,N2,N2-dimethyl-1-phenyl-,(1S)-(9CI)(702699-84-1)

Safety Data

• Hazardous Substances Data: 702699-84-1(Hazardous Substances Data)

Usage

General Description

1,2-Ethanediamine, N2, N2-dimethyl-1-phenyl, (1S)-(9CI) is a chemical compound with the molecular formula C10H18N2. It is also known as N,N'-dimethyl-1,2-phenylenediamine. 1,2-Ethanediamine,N2,N2-dimethyl-1-phenyl-,(1S)-(9CI) is a derivative of 1,2-ethanediamine, also known as ethylenediamine, and is commonly used as a reagent in organic synthesis. It is a colorless to light yellow liquid with a strong and unpleasant odor. 1,2-Ethanediamine,N2,N2-dimethyl-1-phenyl-,(1S)-(9CI) is primarily used in the production of dyes, polymers, and pharmaceuticals. It is important to handle this chemical with caution as it may cause skin irritation, respiratory tract irritation, and eye irritation. Overall, 1,2-Ethanediamine, N2, N2-dimethyl-1-phenyl, (1S)-(9CI) is a versatile compound with applications in various industries.

Upstream product

• 2900-27-8 (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid 
• 367258-45-5 (dimethylcarbamoyl-phenyl-methyl)-carbamic acid tert-butyl ester 
• 20989-17-7 (2S)-2-phenylglycinol 
• 117049-14-6 tert-butyl N-[(1S)-2-hydroxy-1-phenylethyl]carbamate 
• 124-40-3 dimethyl amine 
• 171001-99-3 (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethyl 4-methylbenzenesulfonate 
• 5491-18-9 (S)-N-(benzyloxycarbonyl)phenylglycine 
• 394734-93-1 (S)-benzyl 2-(dimethylamino)-2-oxo-1-phenylethylcarbamate 

Downstream Products

• 1041013-37-9 (S)-N-(2-(dimethylamino)-1-phenylethyl)-3-(2-fluorobenzamido)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 
• 1240474-61-6 4-((S)-2-dimethylamino-1-phenyl-ethylamino)-quinazoline-8-carboxamide 
• 1229900-81-5 (4S,5R,6R)-2-(acetoxymethyl)-6-(3-((S)-2-(dimethylamino)-1-phenylethyl)thioureido)tetrahydro-2H-pyran-3,4,5-triyl triacetate 

Relevant articles and documents

Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers

Herein, we report the discovery of a novel class of quinazoline carboxamides as dual p70S6k/Akt inhibitors for the treatment of tumors driven by alterations to the PI3K/Akt/mTOR (PAM) pathway. Through the screening of in-house proprietary kinase library, 4-benzylamino-quinazoline-8-carboxylic acid amide 1 stood out, with sub-micromolar p70S6k biochemical activity, as the starting point for a structurally enabled p70S6K/Akt dual inhibitor program that led to the discovery of M2698, a dual p70S6k/Akt inhibitor. M2698 is kinase selective, possesses favorable physical, chemical, and DMPK profiles, is orally available and well tolerated, and displayed tumor control in multiple in vivo studies of PAM pathway-driven tumors.

Pd(II)-Catalyzed Enantioselective C(sp3)-H Arylation of Free Carboxylic Acids

A monoprotected aminoethyl amine chiral ligand based on an ethylenediamine backbone was developed to achieve Pd-catalyzed enantioselective C(sp3)-H arylation of cyclopropanecarboxylic and 2-aminoisobutyric acids without using exogenous directing groups. This new chiral catalyst affords new disconnection for preparing diverse chiral carboxylic acids from simple starting materials that are complementary to the various ring forming approaches.

Discovery of pyrroloaminopyrazoles as novel PAK inhibitors

The P21-activated kinases (PAK) are emerging antitumor therapeutic targets. In this paper, we describe the discovery of potent PAK inhibitors guided by structure-based drug design. In addition, the efflux of the pyrrolopyrazole series was effectively reduced by applying multiple medicinal chemistry strategies, leading to a series of PAK inhibitors that are orally active in inhibiting tumor growth in vivo.